Clover Health Investments, Corp. (CLOV) Cash Flow Statement

The positive OCF in Q2 2026, despite a net income of $28.0M, suggests that the company is now converting underwriting profits into cash, a stark contrast to the prior year's losses. The sequential improvement from Q1 2026's $107.9M OCF, which was inflated by timing, indicates a more sustainable cash generation profile. This aligns with the reported combined ratio improvement to 96.2%, implying that premium inflows are outpacing claims outflows, a key driver of float.

The increase in claims payments is consistent with the 55.6% revenue growth, but the pace of claims growth slightly exceeds premium growth, suggesting a potential near-term pressure on the medical care ratio. However, the company's ability to maintain a sub-100% combined ratio indicates that the Clover Assistant may be helping to control medical costs. Investors should monitor whether claims inflation, particularly from high-cost specialty drugs, could erode underwriting margins in future quarters.

The minimal net investment activity suggests that Clover is not relying on portfolio gains to fund operations, which is prudent given its focus on underwriting profitability. The small scale of investment income, as noted in the income statement analysis, means that cash flow is primarily driven by operational performance. This stability in portfolio cash flows provides a buffer, but the company's cash position remains modest relative to its claims liabilities, warranting continued monitoring.

While the ratio is close to 1, the historical volatility—ranging from -5.46 to 12.79—indicates that quarterly cash flows are subject to significant timing differences, likely due to premium and claims settlement cycles. The positive net income in Q2 2026 may include non-cash items such as reserve releases, which are not reflected in OCF. This warrants a deeper examination of the components of net income to ensure that profitability is sustainable and not merely an accounting artifact.

The minimal buyback activity, which turned negative in prior quarters (e.g., -$7.9M in Q1 2026), suggests that management is not aggressively returning capital to shareholders, likely to conserve liquidity for growth and regulatory requirements. This is consistent with the company's pivot toward profitable growth and its need to maintain adequate statutory capital. Investors should view the lack of dividends as a sign that cash is being reinvested into the business, but the sustainability of this approach depends on continued operational cash generation.